首页> 外国专利> Compositions and Methods for treatment in clinical applications of broad-spectrum, undifferentiated or combined

Compositions and Methods for treatment in clinical applications of broad-spectrum, undifferentiated or combined

机译:广谱,未分化或合并的临床应用的组合物和治疗方法

摘要

This report introduces the composition and methods of the improved passive immunity. In a manner, it provides an ingredient that includes a specific polychlorinated antibody synergy in the carrier matrix. This description provides a cost-effective and effective ingredient and method for the treatment of diarrhea and intestinal infection, with a wide range of clinical applications, Non differential or complex requirement 1: ingredients with the following characteristics: (a) non neonatal effective quantity with at least one specific can molecule or its fragments,1. Extract and specifically bind antigens from animals, in which specific can molecules are selected from immunoglobulin, antibody, peptide, variable lymphocyte receptor, cell receptor, transfer factor and mixture; (b) A matrix of vectors in which at least two components are from a group of non-human animals, including enzymes, lactate ferrina, transfer agents, non-specific immunoglobulins, cells, leukocytes, supplement components, interference agents and cellulose,At least one specific linker and at least two carrier matrix components are from different animals. Requirement 4: any ingredient meeting the requirements of items 1 to 3, which is characterized by that the antigen includes a pathogen, a toxin related pathogen, an attachment related pathogen, an undesirable strain or combination thereof. Claim 6: ingredients determined in accordance with claim 4, characterized by pathogens selected from a group consisting of Campylobacter jejuni, Salmonella, Salmonella enterica serovar Typhi, Shigella dystenterie,Plesiomonas shigelloides, Escherichia coli, enteropathogenic E. coli, enterotoxigenic E. coli, enteroaggregative E. coli, enteroinvasive E. coli, hemorrhagic E. coli, Clostridium difficulty, Yersinia enterocolitica, Vibrio cholerae O1, Vibrio O139, Non-O1 Vibrios, Vibrio, Vibrio, Vibrio, Vibrio parahaemolyticus, Aeromonas hydrophila, Clostridium perfringens, Helicobacter enterohepatic, Helicobacter pylori, Staphylococcus aureus, Klebsiella, Gardnerella spp.,Neisseria gonorrhoeae Chlamydiaceae trachomatis Mycoplasma sppCampylobacter jejuni, Trichomonas vaginalis, herpesvirus type 1, herpesvirus type 2, albicans Candida, glabra, tropicalis, parapsiplis and Candida krusei, Streptoccus spp.a, rotavirus, coronavirus, norovirus, calvirus, enterogastric adenoma virus, citomegolavirus, astrovirus, s.pnemoniae, h.influnzae, Neisseria gonorrhea, zoster herpesvirus, polioAnd cliff dance
机译:本报告介绍了改善的被动免疫力的组成和方法。以某种方式,其提供了在载体基质中包括特定多氯抗体协同作用的成分。本说明提供了一种具有成本效益的有效成分和方法,用于腹泻和肠道感染的治疗,具有广泛的临床应用。非差异或复杂的要求1:具有以下特征的成分:(a)非新生儿有效量,具有至少一个特定的罐分子或其片段1。从动物中提取并特异性结合抗原,其中的特异性罐头分子选自免疫球蛋白,抗体,肽,可变淋巴细胞受体,细胞受体,转移因子和混合物; (b)载体矩阵,其中至少两种组分来自一组非人类动物,包括酶,乳酸铁,转移剂,非特异性免疫球蛋白,细胞,白细胞,补充组分,干扰剂和纤维素,至少一种特异性接头和至少两种载体基质组分来自不同的动物。要求4:满足第1至3项要求的任何成分,其特征在于所述抗原包括病原体,与毒素有关的病原体,与附着有关的病原体,不良菌株或其组合。 6.根据权利要求4所述的成分,其特征在于,所述病原体选自空肠弯曲菌,沙门氏菌,肠炎沙门氏菌,伤寒沙门氏菌,痢疾志贺氏菌,志贺氏假单胞菌,大肠杆菌,肠病原性大肠杆菌,肠毒素原性大肠杆菌,肠聚集性大肠杆菌。大肠杆菌,肠溶性大肠杆菌,出血性大肠杆菌,梭菌困难,小肠结肠炎耶尔森菌,霍乱弧菌O1,霍乱弧菌O139,非O1弧菌,弧菌,弧菌,弧菌,副溶血弧菌,亲水性嗜水气单胞菌,产气荚膜梭菌,肠炎曲霉菌幽门螺杆菌,金黄色葡萄球菌,克雷伯氏菌,加德纳菌属,沙门氏菌,沙眼衣原体,空肠弯曲菌,空肠毛滴虫,1型疱疹病毒,2型疱疹念珠菌,副杆菌,念珠菌,光滑,热带,冠状病毒,诺如病毒,杯状病毒,肠胃腺瘤病毒,citolagolavirus ,星状病毒,链球菌,流感嗜血杆菌,淋病奈瑟菌,带状疱疹病毒,小儿麻痹症和悬崖舞

著录项

  • 公开/公告号AR083973A1

    专利类型

  • 公开/公告日2013-04-10

    原文格式PDF

  • 申请/专利权人 PANTHERYX INC.;

    申请/专利号AR2011P104369

  • 发明设计人

    申请日2011-11-23

  • 分类号A61K39/395;A61K35/12;A61K38/17;

  • 国家 AR

  • 入库时间 2022-08-21 16:42:29

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号